| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
109,470,000 |
| Market
Cap: |
76.69(M) |
| Last
Volume: |
627,989 |
Avg
Vol: |
626,236 |
| 52
Week Range: |
$0.5601 - $1.41 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxart is a clinical-stage biotechnology company primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology proprietary oral vaccine platform. Co.'s oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Co.'s investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. In addition, Co. is in early development of its first therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$31,240 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cummings James F. |
Chief Medical Officer |
• • – |
2024-03-28 |
4 |
D |
$1.30 |
$4,280 |
D/D |
(3,292) |
326,801 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2024-03-28 |
4 |
D |
$1.30 |
$5,073 |
D/D |
(3,902) |
355,695 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
241,808 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
420,122 |
|
- |
|
| Lo Steven |
President, Chief Exec Officer |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
250,000 |
|
- |
|
| Berg Edward B |
SVP, General Counsel |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
270,706 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
330,093 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2024-02-02 |
4 |
D |
$1.20 |
$11,064 |
D/D |
(9,220) |
330,122 |
|
- |
|
| Berg Edward B |
SVP, General Counsel |
• • – |
2024-02-02 |
4 |
D |
$1.20 |
$11,064 |
D/D |
(9,220) |
180,706 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2024-02-02 |
4 |
D |
$1.20 |
$9,558 |
D/D |
(7,965) |
240,093 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2023-12-15 |
4 |
D |
$0.63 |
$3,744 |
D/D |
(5,943) |
151,808 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2023-12-08 |
4 |
D |
$0.71 |
$24,957 |
D/D |
(35,151) |
157,751 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2023-12-08 |
4 |
D |
$0.71 |
$24,344 |
D/D |
(34,288) |
339,342 |
|
- |
|
| Berg Edward B |
SVP, General Counsel |
• • – |
2023-12-08 |
4 |
D |
$0.71 |
$23,964 |
D/D |
(33,752) |
189,926 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2023-12-08 |
4 |
D |
$0.71 |
$22,300 |
D/D |
(31,409) |
248,058 |
|
- |
|
| Wheadon David E. |
Director |
• • – |
2023-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
14,750 |
|
- |
|
| Yedid Robert A. |
Director |
• • – |
2023-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
18,490 |
|
- |
|
| Watson W. Mark |
Director |
• • – |
2023-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
42,125 |
|
- |
|
| Heron Elaine J |
Director |
• • – |
2023-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,922 |
24,566 |
|
- |
|
| Finney Michael J. |
Director |
• • – |
2023-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
7,375 |
670,840 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2023-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
192,902 |
|
- |
|
| Tucker Sean |
SVP, Chief Scientific Officer |
• • – |
2023-03-28 |
4 |
D |
$0.75 |
$2,762 |
D/D |
(3,683) |
373,630 |
|
- |
|
| Lee Phillip E |
Chief Financial Officer |
• • – |
2023-03-17 |
4/A |
A |
$0.00 |
$0 |
D/D |
101,652 |
170,402 |
|
- |
|
| Cummings James F. |
Chief Medical Officer |
• • – |
2023-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
194,350 |
238,100 |
|
- |
|
| Floroiu Cezar Andrei |
President, Chief Exec Officer |
• • – |
2023-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
367,735 |
452,735 |
|
- |
|
187 Records found
|
|
Page 1 of 8 |
|
|
0.01 (1.97%) 
